First-Time-in-Human Study of GSK5471713 for Adults with Advanced Prostate Cancer
Sponsor: GlaxoSmithKline
Sponsor score: 60
ClinicalTrials ID:NCT07332455
This clinical trial is testing a new drug, GSK5471713, to see if it is safe and effective for treating adults with advanced prostate cancer that has spread and is resistant to standard hormone therapy.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
The purpose of this study is to evaluate the safety and effectiveness of a new drug called GSK5471713 in adults with advanced prostate cancer that has spread and is no longer responding to hormone therapy. Researchers will assess how the drug is processed in the body, its effects on the cancer, and any potential benefits or risks associated with its use.
Eligibility Criteria
Inclusion Criteria
- Have advanced prostate cancer confirmed by lab tests.
- Cancer must have progressed despite ongoing hormone therapy.
- Be in good overall health with an ECOG performance status of 0 or 1, meaning fully active or restricted in physically strenuous activity but ambulatory.
- Have previously tried hormone therapy and at least one other treatment for prostate cancer.
Exclusion Criteria
- Have a type of prostate cancer other than adenocarcinoma, such as small cell or neuroendocrine carcinoma.
- Have significant heart problems or other serious medical conditions.
- Have uncontrolled infections or significant lab abnormalities.
- Have previously received certain targeted therapies for prostate cancer.
Locations
| FACILITY | ZIP | CITY | STATE |
|---|---|---|---|
| GSK Investigational Site | 49546 | Grand Rapids | Michigan |
| GSK Investigational Site | 19107 | Philadelphia | Pennsylvania |
| GSK Investigational Site | 84119 | West Valley City | Utah |
Get This Program In Your Inbox
Receive detailed information about this treatment opportunity to review with your healthcare provider.